Ice Cream Recalled Nationwide As Warning Issued Over Products
The decision followed a label audit which revealed that although the products list "cream," they do not explicitly declare "milk"—that could endanger those allergic to milk.
Newsweek contacted the company for comment on Sunday via email outside of usual working hours.
Milk is a major allergen under federal labeling laws, and its accidental presence in products poses a risk to consumers with allergies or severe sensitivities.
Undeclared ingredients can trigger life-threatening reactions, making accurate labeling a critical public health requirement.
The company announcement, published on the Food and Drug Administration (FDA)'s website on Saturday, states: "Tropicale Foods of Ontario, CA is recalling certain Helados Mexico and La Michoacana products with specific best by dates, as detailed below because these products contain undeclared milk.
"Though these products include 'cream' in the product ingredient lists, the common name 'milk' is not declared. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products."
Affected items include single-flavor offerings (such as Coconut, Strawberry, Bubble Gum, Cookies and Cream, Mango), as well as multi-packs (6‑pack, 12‑pack, 16‑pack varieties). The recalled products are as follows:
Photos of the affected products are available on the FDA website.
The recall covers a wide range of "best by" dates from May 2026 through July 2027. Distribution spanned retail locations nationwide across the U.S.
As of the FDA announcement, one consumer illness has been reported. Consumers with affected items who are allergic or sensitive to milk are advised not to consume the products and to properly dispose of them.
Food Allergy Research and Education (FARE) states on its website: "When a person with a milk allergy is exposed to milk, proteins in the milk bind to specific antibodies made by the person's immune system. This triggers the person's immune defenses, leading to reaction symptoms that can be mild or very severe."
Consumers who have the affected product should dispose of and not consume this product if allergic or sensitive to milk, and consult medical advice if symptoms arise.
Anyone with queries may contact the company at 909-563-3090 between 8 am and 5 pm Pacific, Monday to Friday.
The FDA will continue oversight and monitor any additional consumer reports or updates.
Related Articles
Is the FDA Doing Enough About Food Additives?Nationwide Ritz Cracker Recall Update as FDA Issues Risk WarningCanned Fruit Recall Sparks Nationwide Warning to CustomersFDA Issues Highest Risk Warning for Tofu Recall
2025 NEWSWEEK DIGITAL LLC.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
FDA Issues Most Serious Risk Level for Cookie Recall
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) has issued its highest risk warning after a California-based company recalled cookies due to potential undeclared allergens. Jalux Americas, Inc, doing business as issued a voluntary recall on July 14 for multiple units of its L'espoir cookies because of undeclared milk, and its Drycapot cookies because of undeclared tree nuts (almond and macadamia nuts). The FDA has now classified the recall as Class I, its most serious category. On its website, the FDA states a Class I is "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death." Newsweek approached Jalux Americas, Inc. via an email outside of office hours for an updated statement. Why it Matters In its original announcement posted on the FDA's website, Jalux Americas, Inc. said that "people who have an allergy or severe sensitivity to milk and/or tree nuts (almond and macadamia nuts) run the risk of serious or life-threatening allergic reaction if they consume these products." A stock image of a split cookie. The FDA has issued a Class I classification, its highest risk category, after California-based Jalux Americas, Inc. initiated a recall of cookie products A stock image of a split cookie. The FDA has issued a Class I classification, its highest risk category, after California-based Jalux Americas, Inc. initiated a recall of cookie products Gavin Woodruff/iStock / Getty Images Plus Food allergies are a significant health concern in the United States, with milk and tree nuts among the nine major food allergens identified under federal law. The others are milk, eggs, fish, crustacean shellfish, peanuts, wheat, soybeans, and sesame. Allergies are an immune system's response to a substance. Allergic reactions can vary in severity from coughing and a runny nose to a life-threatening reaction known as anaphylaxis. According to the CDC's National Center for Health Statistics, almost 6 percent of U.S. adults and children have a food allergy. What To Know The recall, announced on July 14, 2025, affects: L'espoir cookies (32 units, UPC: 4 942737 200147, code: L4FN, best before 09/26/2025) for undeclared milk Drycapot cookies (28 units, UPC: 4 942737 210191, code: D4FN, best before 09/26/2025) for undeclared tree nuts (almond and macadamia nut) The products were distributed in California, Illinois, and Washington and sold exclusively at retail locations in Torrance, CA, and San Jose, CA, Arlington Heights, IL; and Lynnwood, WA. The L'espoir cookies were on sale from May 26 to June 30, 2025, and the Drycapot cookies from May 31 to June 30, 2025. No online sales occurred. Product images released by Jalux Americas, the FDA alongside a product recall of L'espoir Brand L'espoir cookies and L'espoir Brand Drycapot cookies Product images released by Jalux Americas, the FDA alongside a product recall of L'espoir Brand L'espoir cookies and L'espoir Brand Drycapot cookies Jalux Americas, Inc./FDA Jalux Americas, Inc. said the recall was "initiated after it was discovered during an inventory audit that L'espoir product containing Milk and the Drycapot product containing Tree Nuts were inadvertently distributed in packaging that did not reveal the presence of those allergens." As of July 17, no illnesses have been reported. In an earlier statement provided to Newsweek, Jalux Americas, Inc. said: "Those who have allergies to the ingredients that were inadvertently undeclared on the labels should refrain from consuming the products and return them to the store where they purchased for a full refund." The company added: "As part of our preventive measures, our supplier partner has added a step at their manufacturing facility to verify that the product matches the label after it is applied, and to record this verification in the production log. Our supplier partner will also reinforce allergy and manufacturing procedure training at the facility." The company further stated, "At the retail store level, we will strengthen our checks during stocking to ensure there are no discrepancies between products and labels, not just for the manufacturer of the recalled products but across all items. We would like to clarify that we have thus far not received any inquiries from consumers regarding this matter." The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." What Happens Next Consumers who have purchased L'espoir L4FN and Drycapot D4FN products with the best before date of 09/26/2025 are urged to return it to the place of purchase for a full refund.
Associated Press
an hour ago
- Associated Press
American Kratom Association Praises Secretary Kennedy and Commissioner Makary for Bold Action to Recommend Scheduling of Dangerous 7-OH Products
Commissioner Makary: 'We are not targeting the kratom leaf' American Kratom Association (AKA) today applauded Secretary Robert Kennedy and FDA Commissioner Dr. Marty Makary for their decisive and science-driven recommendation to classify 7-hydroxymitragynine (7-OH) as a Schedule I substance under the federal Controlled Substances Act. This bold step is a critical milestone in protecting public health and consumer safety from dangerous synthetic products that masquerade as natural kratom. 'Secretary Kennedy and Commissioner Makary have shown exceptional leadership in confronting one of the most urgent public health threats related to mislabeled, manipulated psychoactive substances,' said Mac Haddow, senior fellow on public policy for the American Kratom Association. 'These 7-OH products are not kratom. They are chemically altered substances that carry potent opioid-like effects and pose an imminent threat to consumers. This move sends a clear and long-overdue message: the safety of the American public comes first.' 7-hydroxymitragynine is a metabolite — not a naturally occurring substance in the kratom plant — and occurs during the drying of kratom leaves at extremely low levels, typically less than 0.01%. However, unscrupulous manufacturers have exploited chemical manipulation to create concentrated 7-OH products that far exceed natural levels, creating high-potency, opioid-like effects that are addictive and potentially lethal. These products are often falsely marketed under the kratom name, misleading consumers and damaging the reputation of natural kratom, which has a vastly different safety profile. The American Kratom Association has worked tirelessly to educate policymakers, regulators, and the public on the difference between natural kratom products and chemically manipulated 7-OH formulations. The AKA has advocated for state-based Kratom Consumer Protection Acts (KCPA) to ban the sale of adulterated and dangerously enhanced products. This federal scheduling recommendation is a landmark development that supports those efforts and establishes a much-needed national framework to protect consumers. 'The FDA's own research shows that natural kratom has a relatively low potential for abuse and may offer harm-reduction benefits when used responsibly,' Haddow continued. 'It is the synthetic manipulation of 7-OH that has created the danger. The action by Secretary Kennedy and Commissioner Makary is not only scientifically justified, it is morally imperative.' The AKA urges swift action by the Drug Enforcement Administration (DEA) to initiate the rule-making process to schedule synthetically manipulated 7-hydroxymitragynine and to make clear that such action does not impact the legal status of natural kratom or its primary alkaloids, mitragynine and unaltered 7-OH occurring within the plant matrix. The goal is to eliminate the threat posed by rogue products while preserving access to safe, regulated kratom. 'We look forward to working with federal agencies and state policymakers to ensure that safe access to natural kratom is protected, while these dangerous imposters are removed from the marketplace,' said Haddow. Note: The FDA also released " Hiding in Plain Sight: 7-OH Products " to help educate the public. About American Kratom Association (AKA) American Kratom Association (AKA) is a consumer-based, nonprofit organization, focused on furthering the latest science as guidance for kratom public policy. AKA works to give a voice to millions of Americans by fighting to protect their rights to access safe and natural kratom. For more information, visit and learn more at Media Contact Mac Haddow [email protected] ### SOURCE: American Kratom Association (AKA) Copyright 2025 EZ Newswire
Associated Press
an hour ago
- Associated Press
Global Kratom Coalition Applauds HHS Crackdown on Dangerous Synthetic Kratom Derivatives
New federal action targets 7-hydroxymitragynine products, while protecting access to natural kratom leaf The Global Kratom Coalition (GKC) today applauded the U.S. Department of Health and Human Services (HHS) for taking decisive action to protect public health by moving to schedule products that contain high concentrations of 7-hydroxymitragynine (7-OH or '7'). Scheduled drugs are those with a high potential for abuse, with no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The announcement, made by Health Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, targets manipulated, high-potency, synthetic products like '7' that are opioids masquerading as dietary supplements and are being sold online and in smoke shops across the country. The introduction of these products in the last two years has raised alarm among public health experts and responsible kratom advocates alike, who warn that these synthetic products pose a serious risk to consumers and undermine the safe, traditional use of kratom leaf. 'The Department of Health and Human Services is showing bold, science-driven leadership by taking aim at these rogue 7-OH products,' said Walker Gallman, legislative director of the Global Kratom Coalition. 'Secretary Kennedy and Commissioner Makary deserve enormous credit for drawing a clear line between dangerous synthetics and the natural plant. This is a huge win for public health and for millions of Americans who responsibly use leaf kratom to improve their quality of life.' HHS made clear that natural leaf kratom is not the target of this action. Federal officials have rightly distinguished between the traditionally used botanical with centuries of safe use and synthetic derivatives like '7,' which pose significant health risks due to their potency and opioid-like effects. This distinction is critical to protect public health while preserving access to natural kratom for the millions of Americans who use it safely and responsibly. Today's announcement follows FDA actions taken earlier this month. The FDA has already begun ramping up enforcement, issuing seven warning letters to manufacturers of 7-OH products. This action sets the stage for stronger measures ahead, including potential product seizures and civil penalties. Today's announcement also featured strong support from Sen. Markwayne Mullin (R-Okla.), who has been an advocate for distinguishing natural leaf kratom from synthetic opioids, as well as powerful testimony from natural leaf kratom consumer Melody Woolf of Kalamazoo, Michigan. Woolf, a longtime advocate for natural kratom, described how natural kratom leaf helped her in her daily life but warned that synthetic 7-OH products represent a dangerous and misleading alternative. 'It was only the powdered kratom leaf that saved my life,' Woolf testified. 'Now I'm seeing something very dangerous happen. 7-OH is being sold over the counter, and it's not the plant. It's concentrated and addictive. People think it's kratom, but it's not. And it's dragging some back toward opioid use. 7-OH needs to be off the shelves.' Gallman added, 'Melody's story is one of thousands. She represents what we're fighting for—access to natural, responsibly regulated kratom. We applaud HHS for standing with consumers like her and protecting them from deceptive, dangerous knockoffs.' The Global Kratom Coalition encourages HHS to work closely with the Drug Enforcement Administration (DEA) to move swiftly through the federal scheduling process for synthetically derived 7-hydroxymitragynine products. Coordinated action is essential to ensure these dangerous, highly concentrated substances are removed from the market before they can cause further harm. By partnering on enforcement and regulation, HHS and DEA can protect consumers while preserving access to safe, natural kratom leaf. About Global Kratom Coalition The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit Media Contact Patrick George +1 916-202-1982 [email protected] ### SOURCE: Global Kratom Coalition Copyright 2025 EZ Newswire
